A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand.
Lijoy VargheseLouise TalbotAndrea GovenderXu-Hao ZhangBruce A MungallPublished in: Applied health economics and health policy (2019)
HO-15-16775.